Viral transduction using poloxamine
By using a composition that combines retroviral vectors and vertebrate cells, the problem of inefficient transduction of viral vectors is solved, and the effect of efficient transduction and reducing clinical trial costs is achieved.
CN113631703BActive Publication Date: 2025-03-25RUIFUDI GENE DELIVERY CO LTD
Patent Information
- Application Number
- CN201980091307.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-12-04
- Filing Date
- 2019-12-04
- Publication Date
- 2025-03-25
- Estimated Expiration
- 2039-12-04
AI Technical Summary
Technical Problem
In the prior art, viral vectors are less efficient in transducing cells, especially in difficult-to-transduce cells such as lymphocytes and tumor cells. The demand for transduction and viral yield is high, resulting in increased clinical trial costs.
Method used
Using a composition containing poloxamine, combining retroviral vectors and vertebrate cells, the low toxicity and low production cost of poloxamine are used to improve the efficiency of viral transduction and reduce the cost of clinical trials.
Benefits of technology
It significantly improves the transduction efficiency of retroviral vectors in vertebrate cells, reduces the demand for viral yields, and reduces the cost of clinical trials.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure BDA0003196803500000191 
Figure BDA0003196803500000201 
Figure FDA0005195268640000064
Abstract
The present invention provides a composition comprising or consisting of the following substances: (a) poloxamine; (b) (i) a retroviral vector; and (ii) a vertebrate cell.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Retroviral transduction using poloxamers
WO2013127964A1
Pseudotyped lentiviral vectors
WO2015104376A1
Retroviral transduction using poloxamers
US20150064788A1